Evaluation of the expression of the immunosuppressive enzyme - Indoleamine 2,3-dioxygenase in ovarian cancer tissue;Ocena ekspresji immunosupresyjnego enzymu 2,3-dioksygenazy indolaminy w tkance raka jajnika

Przeglad Menopauzalny

Volumn 17, Issue 3, 2013, Pages 223-227

  Rogala, Ewelina ^a   Nowicka, Aldona ^a   Bednarek, Wiesława ^a   Barczyński, Bartłomiej ^a   Piekarczyk, Wanda ^a   Klimek, Katarzyna ^b   Zakrzewski, Maciej ^a   Kotarski, Jan ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b Samodzielny Publiczny Szpital Kliniczny Nr 1 ^*  (Poland)

Author keywords

Immune tolerance; Indoleamine 2,3 dioxygenase; Ovarian cancer

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; MESSENGER RNA;

ADVANCED CANCER; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; MENOPAUSE; NATURAL KILLER CELL; OVARY CARCINOMA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

EID: 84884485730     PISSN: 16438876     EISSN: None     Source Type: Journal    
DOI: 10.5114/pm.2013.36587     Document Type: Article

References (19)

1. McGuire III W.P., Markman M. Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer 2003; 89 Suppl. S3-8. (Pubitemid 38067997)
2. Marzec-Kotarska B., Kotarski J, Cybulski M., et al Ekspresja genu podoplaniny w złośliwych nowotworach jajnika. Prz Menopauz 2011; 12: 102-5.
3. Pectasides D, Fountzilas G, Aravantinos G., et al Epithelial ovarian carcinoma in younger vs older women: is age an independent prognostic factor? The Hellenic Oncology Cooperative Group experience. Int J Gynecol Cancer 2007; 17: 1003-10. (Pubitemid 47414824)
4. Vo C, Carney ME Ovarian cancer hormonal and environmental risk effect. Obstet Gynecol Clin North Am 2007; 34: 687-700. (Pubitemid 350182430)
5. Uytlenhove C, Pilotte L, Theatev I., et al Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleami ne 2,3-dioksygenase. Nat Med 2003; 9: 1269-74. (Pubitemid 37279849)
6. Wertel I, Polak G, Barczyński B, et al Subpopulacje komórek dendrytycznych krwi obwodowej w przebiegu chemioterapii raka jajnika. Ginekol Pol 2007; 78: 768-71.
7. Whiteside TI. Immune suppression in cancer: effects on immune cells, mechanism and future therapeutic intervention. Semin Cancer Biol 2006; 16: 3-15.
8. Muller AJ, DuHadaway JB, Donover P.S., et al Inhibition of indoleamine 2,3-dioksygenase an immunomodulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005; 11: 312-9. (Pubitemid 40460560)
9. Munn DH, Zhou M, Attwood J.T., et al Prevention of allogenic fatal rejection by tryptophan catabolism. Science 1998; 281: 1191-3. (Pubitemid 28406294)
10. Frumento G, Rotondo R, Tonetti M., et al Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 2002; 196: 459-68.
11. Della Chiesa M., Carlomagno S, Frumento G., et al The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood 2006; 108: 4118-25. (Pubitemid 44913283)
12. Munn DH, Sharma MD, Hou D, et al Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004; 114: 280-90. (Pubitemid 39071633)
13. Inaba T, Ino K, Kajiyama H., et al Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy. Gynecol Oncol 2010; 117: 423-8.
14. Ino K, Yoshida N, Kajiyama H., et al Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer 2006; 95: 1555-61. (Pubitemid 44863359)
15. Okamoto A, Nikaido T, Ochiai K., et al Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 2005; 11: 6030-9. (Pubitemid 41170335)
16. Takao M, Okamoto A, Nikaido T., et al Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer. Oncol Rep 2007; 17: 1333-9.
17. Inaba T, Ino K, Kajiyama H., et al Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. Gynecol Oncol 2009; 115: 185-92.
18. Nonaka H, Saga Y, Fujiwara H., et al Indoleamine 2,3-dioxygenase promotes peritoneal dissemination of ovarian cancer through inhibition of natural killer cell function and angiogenesis promotion. Int J Oncol 2011; 38: 113-20.
19. Qian F, Villella J, Wallace P.K., et al Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3- dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer. Cancer Res 2009; 69: 5498-504.